Improving the Therapeutic Efficacy of Oncolytic Viruses for Cancer: Targeting Macrophages

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2023 Nov 23

PMID 37993941

Authors

Zhen Shen

Xiyu Liu

Guixiang Fan

Jintong Na

Qiaoqiao Liu

Faquan Lin

Zhikun Zhang

Liping Zhong

Affiliations

Soon will be listed here.

Abstract

Oncolytic viruses (OVs) for cancer treatment are in a rapid stage of development, and the direct tumor lysis and activation of a comprehensive host immune response are irreplaceable advantages of cancer immunotherapy. However, excessive antiviral immune responses also restrict the spread of OVs in vivo and the infection of tumor cells. Macrophages are functionally diverse innate immune cells that phagocytose tumor cells and present antigens to activate the immune response, while also limiting the delivery of OVs to tumors. Studies have shown that the functional propensity of macrophages between OVs and tumor cells affects the overall therapeutic effect of oncolytic virotherapy. How to effectively avoid the restrictive effect of macrophages on OVs and reshape the function of tumor-associated macrophages in oncolytic virotherapy is an important challenge we are now facing. Here, we review and summarize the complex dual role of macrophages in oncolytic virotherapy, highlighting how the functional characteristics of macrophage plasticity can be utilized to cooperate with OVs to enhance anti-tumor effects, as well as highlighting the importance of designing and optimizing delivery modalities for OVs in the future.

Citing Articles

Bacterial-Mediated In Situ Engineering of Tumour-Associated Macrophages for Cancer Immunotherapy.

Kuhl G, Tangney M Cancers (Basel). 2025; 17(5).

PMID: 40075571 PMC: 11899205. DOI: 10.3390/cancers17050723.

Unmasking the potential: mechanisms of neuroinflammatory modulation by oncolytic viruses in glioblastoma.

Beder N, Mirbahari S, Belkhelfa M, Mahdizadeh H, Totonchi M Explor Target Antitumor Ther. 2025; 6:1002294.

PMID: 40061139 PMC: 11886384. DOI: 10.37349/etat.2025.1002294.

Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review.

Borella F, Carosso M, Chiparo M, Ferraioli D, Bertero L, Gallio N Pathogens. 2025; 14(2).

PMID: 40005517 PMC: 11858389. DOI: 10.3390/pathogens14020140.

The Potential of Oncolytic Virotherapy in the Treatment of Head and Neck Cancer: A Comprehensive Review.

Spirito F, Nocini R, Mori G, Albanese M, Georgakopoulou E, Sivaramakrishnan G Int J Mol Sci. 2024; 25(23).

PMID: 39684701 PMC: 11641702. DOI: 10.3390/ijms252312990.

Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.

Jirovec E, Quixabeira D, Clubb J, Pakola S, Kudling T, Arias V J Exp Clin Cancer Res. 2024; 43(1):297.

PMID: 39506856 PMC: 11539705. DOI: 10.1186/s13046-024-03219-0.

References

Nguyen H, Guz-Montgomery K, Saha D . Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy. Cells. 2020; 9(2). PMC: 7072539. DOI: 10.3390/cells9020400. View

Cortese N, Carriero R, Laghi L, Mantovani A, Marchesi F . Prognostic significance of tumor-associated macrophages: past, present and future. Semin Immunol. 2020; 48:101408. DOI: 10.1016/j.smim.2020.101408. View

Fu Y, Lin Q, Zhang Z, Zhang L . Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm Sin B. 2020; 10(3):414-433. PMC: 7049610. DOI: 10.1016/j.apsb.2019.08.010. View

Harrington K, Freeman D, Kelly B, Harper J, Soria J . Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019; 18(9):689-706. DOI: 10.1038/s41573-019-0029-0. View

Wang H, Shao Q, Wang J, Zhao L, Wang L, Cheng Z . Decreased CXCR2 expression on circulating monocytes of colorectal cancer impairs recruitment and induces Re-education of tumor-associated macrophages. Cancer Lett. 2022; 529:112-125. DOI: 10.1016/j.canlet.2022.01.004. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

Jakeman P, Hills T, Fisher K, Seymour L . Macrophages and their interactions with oncolytic viruses. Curr Opin Pharmacol. 2015; 24:23-9. DOI: 10.1016/j.coph.2015.06.007. View

Sugawara K, Iwai M, Yajima S, Tanaka M, Yanagihara K, Seto Y . Efficacy of a Third-Generation Oncolytic Herpes Virus G47Δ in Advanced Stage Models of Human Gastric Cancer. Mol Ther Oncolytics. 2020; 17:205-215. PMC: 7178322. DOI: 10.1016/j.omto.2020.03.022. View

Sun Y, Zhang Z, Zhang C, Zhang N, Wang P, Chu Y . An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition. Mol Ther Oncolytics. 2022; 26:105-119. PMC: 9233193. DOI: 10.1016/j.omto.2022.05.008. View

10.

Friedman G, Johnston J, Bag A, Bernstock J, Li R, Aban I . Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. N Engl J Med. 2021; 384(17):1613-1622. PMC: 8284840. DOI: 10.1056/NEJMoa2024947. View

11.

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

12.

Fusciello M, Fontana F, Tahtinen S, Capasso C, Feola S, Martins B . Artificially cloaked viral nanovaccine for cancer immunotherapy. Nat Commun. 2019; 10(1):5747. PMC: 6917704. DOI: 10.1038/s41467-019-13744-8. View

13.

Nobs S, Kopf M . Tissue-resident macrophages: guardians of organ homeostasis. Trends Immunol. 2021; 42(6):495-507. DOI: 10.1016/j.it.2021.04.007. View

14.

Adair R, Roulstone V, Scott K, Morgan R, Nuovo G, Fuller M . Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med. 2012; 4(138):138ra77. PMC: 3893925. DOI: 10.1126/scitranslmed.3003578. View

15.

Josephs S, Ichim T, Prince S, Kesari S, Marincola F, Escobedo A . Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. J Transl Med. 2018; 16(1):242. PMC: 6119315. DOI: 10.1186/s12967-018-1611-7. View

16.

Ma R, Li Z, Chiocca E, Caligiuri M, Yu J . The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2022; 9(2):122-139. PMC: 9877109. DOI: 10.1016/j.trecan.2022.10.003. View

17.

Zhang H, Xie W, Zhang Y, Dong X, Liu C, Yi J . Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model. Cancer Gene Ther. 2021; 29(5):456-465. PMC: 9113929. DOI: 10.1038/s41417-021-00389-3. View

18.

Christofides A, Strauss L, Yeo A, Cao C, Charest A, Boussiotis V . The complex role of tumor-infiltrating macrophages. Nat Immunol. 2022; 23(8):1148-1156. PMC: 10754321. DOI: 10.1038/s41590-022-01267-2. View

19.

Locati M, Curtale G, Mantovani A . Diversity, Mechanisms, and Significance of Macrophage Plasticity. Annu Rev Pathol. 2019; 15:123-147. PMC: 7176483. DOI: 10.1146/annurev-pathmechdis-012418-012718. View

20.

Li M, Li G, Kiyokawa J, Tirmizi Z, Richardson L, Ning J . Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta Neuropathol Commun. 2020; 8(1):221. PMC: 7730751. DOI: 10.1186/s40478-020-01096-0. View